García Cárceles, J., Brea, J., Vázquez Villa, M. D. H., Ladron de Guevara-Miranda, D., Cincilla, G., Sánchez Martínez, M., . . . López Rodríguez, M. L. (2022). 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson’s Disease.
Citación estilo ChicagoGarcía Cárceles, Javier, et al. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson’s Disease. 2022.
Cita MLAGarcía Cárceles, Javier, et al. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1 Receptor for Parkinson’s Disease. 2022.